Kamada Reports Record Q2 2026 Results and Affirms Annual Guidance

Key Facts

In a move reflecting the robust performance of the specialty biopharmaceutical sector, Kamada Ltd. announced the strongest financial results in its history for the first half and second quarter of 2026. According to reports, this record performance was driven by double-digit profitable growth across its portfolio of plasma-derived therapies. Consequently, the company has affirmed its full-year 2026 financial guidance, signaling confidence in its operational trajectory.

These record results are underpinned by strong sales growth, with the company projecting annual revenues between $200 million and $205 million and adjusted EBITDA between $50 million and $53 million. This outlook represents a 12% increase in revenue and a 23% rise in adjusted EBITDA compared to the previous year. Per financial data, Kamada held cash and short-term investments totaling $70.1 million as of June 30, 2026, compared to $75.5 million at the end of 2025.

Looking ahead, investors are focusing on the company's ability to convert record profitability into consistent cash flows and expand its commercial portfolio. While current price levels for KMDA are unavailable at this time, the market remains attentive to financial stability in the second half of the year. Additionally, upcoming macroeconomic catalysts such as U.S. Initial Jobless Claims may influence broader investor sentiment toward mid-cap healthcare stocks.